TheStreet upgraded shares of XOMA (NASDAQ:XOMA) from a d rating to a c rating in a report published on Tuesday morning, TheStreetRatingsTable reports.
A number of other equities research analysts have also recently commented on XOMA. HC Wainwright raised their price objective on XOMA from $30.00 to $56.00 and gave the company a buy rating in a research note on Tuesday, January 19th. Zacks Investment Research raised shares of XOMA from a sell rating to a hold rating in a research report on Tuesday, March 16th.
Shares of XOMA stock opened at $38.60 on Tuesday. The business’s 50 day simple moving average is $37.85 and its 200 day simple moving average is $33.85. XOMA has a one year low of $15.48 and a one year high of $46.32. The stock has a market capitalization of $434.37 million, a PE ratio of -34.77 and a beta of 1.26. The company has a debt-to-equity ratio of 0.61, a current ratio of 4.63 and a quick ratio of 4.63.
In other XOMA news, Director Bvf Partners L. P/Il sold 569,797 shares of XOMA stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $38.36, for a total transaction of $21,857,412.92. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 9.89% of the company’s stock.
Large investors have recently bought and sold shares of the business. Citigroup Inc. boosted its stake in shares of XOMA by 105.0% in the 4th quarter. Citigroup Inc. now owns 1,665 shares of the biotechnology company’s stock worth $73,000 after buying an additional 853 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of XOMA by 18.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,693 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 425 shares during the period. Old Well Partners LLC purchased a new stake in XOMA in the 4th quarter worth about $205,000. Rhumbline Advisers purchased a new stake in XOMA in the 4th quarter worth about $243,000. Finally, Infrastructure Capital Advisors LLC bought a new stake in XOMA in the 4th quarter valued at about $210,000. Hedge funds and other institutional investors own 57.21% of the company’s stock.
XOMA Company Profile
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Featured Story: Growth Stocks
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.